The fastest way to know whether semaglutide or tirzepatide is right for you is the same way we figure it out at consultation: BMI, comorbidities, contraindications, labs, and goals. Here is the framework — including the patients we deliberately decline to prescribe for.
Before any of the nuance, the FDA-labeled criteria for the obesity indication of semaglutide (Wegovy) and tirzepatide (Zepbound) are clear. You are eligible if you meet either:
Tirzepatide is also FDA-approved for obstructive sleep apnea in adults with obesity (regardless of weight goals). Semaglutide is approved as adjunct therapy for type 2 diabetes and for cardiovascular event reduction in patients with established CV disease.
No GLP-1 prescription leaves the practice without a baseline panel. The labs serve three purposes: confirm eligibility, identify confounders, and establish a baseline against which response is measured.
| Test | Why we order it |
|---|---|
| Comprehensive metabolic panel (CMP) | Liver enzymes (ALT/AST), kidney function (creatinine, GFR), electrolytes, glucose |
| Hemoglobin A1c | Diabetes status; baseline for tracking glycemic response |
| Fasting insulin + glucose | HOMA-IR calculation; identifies insulin resistance not yet meeting diabetes criteria |
| Lipid panel | Baseline LDL, HDL, triglycerides; identifies dyslipidemia comorbidity |
| Thyroid panel (TSH, free T4, free T3, TPO) | Rule out subclinical hypothyroidism that mimics weight resistance; document baseline for MTC risk discussion |
| Hormones — sex (testosterone, estradiol, SHBG, LH/FSH, progesterone in women) | Hypogonadism caps weight-loss response; perimenopausal hormone shifts drive much of midlife weight gain |
| hs-CRP | Inflammatory burden; metabolic disease marker |
| Vitamin D, B12 | Common deficiencies; B12 absorption affected by metformin (often co-prescribed) |
| Pregnancy test (women of childbearing age) | Required before initiation |
| DEXA or InBody body composition | Baseline lean mass and visceral fat distribution; tracks lean-mass preservation during therapy |
If labs surface confounders (subclinical hypothyroidism, hypogonadism, B12 deficiency), we treat those first — often, weight starts moving before any GLP-1 is added.
Tolerability assessment, dose decision (escalate or hold), GI symptom audit. Telehealth.
Repeat A1c, lipids, CMP. Body composition (DEXA or InBody). Adjust dose, titrate adjuncts.
Full re-evaluation. Are we hitting weight-loss target? Lean-mass preservation? Comorbidity remission?
Maintenance dose decision, taper-and-hold strategy, exit-plan refinement.
Patients on TRT or BHRT have hormones repeated every 12 weeks during the cut. Patients with diabetes have additional monitoring per ADA guidelines. Patients with prior pancreatitis history (a relative contraindication) have closer surveillance.
Several patient profiles meet FDA criteria but get a different first-line recommendation from us:
None of these are permanent rejections. They are sequencing decisions. Sometimes the answer is "GLP-1 in three months, after we fix what's underneath."
Our consultation answers the candidate question on the basis of your labs, history, and goals — not a Google quiz. If a GLP-1 is right for you, we prescribe and monitor. If something else is the right first lever, we say so.
Book a Consultation Founding Membership